Design of a semi-synthetic (polymyxin-B•NHS-LC-biotin)4lavidin tetramer and evaluation of its ability to inhibit lipopolysaccharide induced TNFα synthesis

Abstract

A method is described for the semi-synthetic production of (polymyxin-B•NHS-LC-biotin)₄lavidin tetramer. In phase I of semi-synthesis procedures, polymyxin-B was reacted with NHS-LC-biotin reagent resulting in the generation of the reactive intermediate, polymyxin-B•NHS-LC-biotin.

In phase II of the conjugation procedure, the polymyxin-B•NHS-LC-biotin complex was combined with purified avidin producing the tetramer complex, (polymyxin-B•NHS-LC-biotin)₄lavidin. A 'long-chain' biotinylation reagent, NHS-LC-biotin minimized steric hinderance phenomenon thereby maximizing the binding of multiple lipopolysaccharide molecules.

Binding avidity of (polymyxin-B•NHS-LC-biotin)₄lavidin for lipopolysaccharide was established with the application of fluorescein isothiocyanate Escherichia coli (055:B5) lipopolysaccharide conjugate (FITC-LPS). Applying a tissue culture based biological assay, (polymyxin-B•NHS-LC-biotin)₄lavidin was capable of inhibiting Salmonella minnesota (RS) lipopolysaccharide induced synthesis of tumor necrosis factorα (TNFα).

Get full access to this article

View all access options for this article.

References

Adhikari M. , Coovadia H.M. , Gaffin S.L. , BrockUtne J G, Marivate M, Pudifin D J. Septicaemic low birthweight neonates treated with human antibodies to endotoxin. Arch Dis Child 1985; 60: 382-384.

Gaffin S.L. Gram-negative bacteraemia: new therapeutic possibilities with antiendotoxin antibodies. Haematol Blood Trans 1985;29: 107-111.

Remick D.G. , Strieter R.M. , Lynch J.P. , Nguyen D. , Eskandari M. , Kunkel S.L. In vivo dynamics of murine tumor necrosis factor-alpha gene expression: kinetics of dexamethazoneinduced suppression. Lab Invest 1989;60 (6): 766-771.

Spengler R.N. , Spengler M.L. , Strieter R.M. , Remick D.G. , Larrick J.W. , Kunkel S.L. Modulation of tumor necrosis factor-alpha gene expression: desensitization of prostaglandin E2-induced suppression. J Immunol 1989; 142: 4346-4350.

Schade U.F. , Ernst M. , Reinke M. Lipoxygenase inhibitors suppress formation of tumor necrosis factor in vitro and in vivo. Biochem Biophys Res Commun 1989 ; 159: 748-758.

Goto F. , Watanabe E. , Maruyama N. Prevention of the toxic action of tumor necrosis factor by cyclo-oxygenase inhibitor and leukopenia. Circ Shock 1989;29: 175-180.

Sheehan K C F. , Ruddle N H. , Schreiber R.D. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol 1989; 142: 3884-3893.

Sherry B A. , Gelin J. , Fong Y. Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J 1989; 3: 1956-1962.

Porteu F. , Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils . J Exp Med 1990; 172: 599-607.

10.

Engelmann H. , Aderka D. , Rubinstein M. , Rotman D. , Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264: 11974-11980.

11.

Seckinger P. , Isaaz S. , Dayer J. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem 1989; 264: 11966-11973.

12.

Dunn D.L. , Mach P.A. , Condie R.M. , Cerra F.B. Anticore endotoxin F(ab')2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis. Surgery 1984; 96: 440-444.

13.

Miner K.M. Characterization of murine monoclonal antibodies to Escherichia coli J5. Infect Immun 1986; 1: 56-62.

14.

Walterspiel J.W. , Kaplan S.L. , Mason E.O. Protective effect of subinhibitory polymyxinB alone and in combination with ampicillin for overwhelming Haemophilus influenzae type B infection in the infant rat: evidence for invivo and invitro release of free endotoxin after ampicillin treatment. Pediatr Res 1986; 20:237-241.

15.

Bannatyne R M. , Cheung R. Infection in neutropenia: Antiendotoxin effect of polymyxin. Anticancer Res 1982; 2: 239-240.

16.

Flynn P.M. , Shenep J.L. , Stokes D.C. , Fairclough D. , Hildner W.K. PolymyxinB moderates acidosis and hypotension in established experimental gram-negative septicemia. J Infect Dis 1987 ; 156: 706-712.

17.

Munster A M. , Xiao G X. , Guo Y. , Wong L A. , Winchurch R A. Control of endotoxemia in bum patients by use of polymyxin B. J Bum Rehab 1989; 10: 327-330.

18.

Hanasawa K. Selective removal of endotoxin from the blood by extracorporeal hemopertusion with polymyxin B immobilized fiber. Prog Clin Biol Res 1988;264: 337-341.

19.

Sande M.A. , Mendell G.L. Antimicrobial agents. In: Gilman A G , Goodman L S , Rall T W , Murad F , eds. The pharmacological basis of therapeutics. New York: MacMillan , 1985: 1191-1192.

20.

Morrison D C. , Jacobs D.M. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry 1976; 13:813-818.

21.

Coyne C.P. , Fenwick B.W. Inhibition of lipopolysaccharide-induced macrophage tumor necrosis factoralpha synthesis by polymyxinB sulfate. Am J Vet Res 1993; 54: 150-163.

22.

Imoto M. , Yshimura N. , Kusumoto S. Total synthesis of lipid A, active principal of bacterial endotoxin. Proc J Acad 1984; 60: 285-290.

23.

Hase S. , Rietschel E.T. Isolation and analysis of the lipid A backbone: lipid A structure of lipopolysaccharides from various bacterial groups. Eur J Biochem 1973; 63: 101-107.

24.

Espevik T. , NissenMeyer J. A highly sensitive cell line, WEHI clone 164 for measuring cytotoxicity factor/tumor necrosis factor from human monocytes. Methods 1990;95: 99-105.

25.

Coyne C P. , Fenwick B W. , Iandolo J. , Griffith G. , Williams D. Isolation of an inhibitor of TNFalpha from activated equine mixed white blood cell populations. Am J Vet Res 1993; 54: 845-855.

26.

Westphal O. , Gmeiner J. , Luderitz O. Chemistry and biology of the lipid A component of enterobacterial lipopolysaccharides. Colloq Int CNRS Paris 1969; 174: 69-78.

27.

Brade H. , Brade L. , Schade U. Structure, endotoxicity, immunogenicity and antigenicity of bacterial lipopolysaccharides (endotoxins, O antigens). In: Levin J , Buller H R , ten Cate J W , van Deventer S J H , Sturk A. eds. Bacterial endotoxins: pathophysiological effects, clinical significance, and pharmacological control. New York: Alan R. Liss, 1988: 17-46.

28.

Chia J K S , Pollack M. , Guelde G. , Koles N.L. , Miller M. , Evans M.E. Lipopolysaccharide (LPS)reactive monoclonal antibodies fail to inhibit LPSinduced tumor necrosis factor secretion by mouse derived macrophages. J Infect Dis 1989; 159: 872-880.

29.

Galanos C. , Luderitz O. , Rietschel E.T. , Westphal O. Newer aspects of the chemistry and biology of bacterial lipopolysaccharides, with special reference to their lipidA components. In: Goodwin T W , ed. International review of biochemistry: biochemistry of lipids II Baltimore: Univ Park Press, 1977: 239-335.

30.

Galanos C. , Luderitz O. , Westphal O. Preparation and properties of antisera against the lipidA component of bacterial lipopolysaccharides. Eur Biochem 1971;24: 116-122.

31.

Galanos C. , Lehmann V. , Luderitz O. , Rietschel E.T. Immunogenic properties of lipidA. Rev Infect Dis 1989; 6: 546-551.

32.

Schollmeier K. Immunologic and pathophysiologic role of tumor necrosis factor. Am J Resp Cell Mol Biol 1990 ; 311: 11-12.

33.

Fong Y. , Lowry S.F. Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin Immunol Immunopathol 1990; 55: 157-170.

34.

Silva A.T. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock. J Infect Dis 1990; 162:421-427.

35.

Hinshaw L.B. , TekampOlson P. , Chang A C K. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNFalpha). Circ Shock 1990; 30: 279-292.

36.

Corrigan J.J. , Bell B.M. Comparison between the polymyxins and gentamicin in preventing endotoxin-induced intravascular coagulation and leukopenia. Infect Immun 1971; 4: 563-566.

37.

Corrigan J.J. , Bell B.M. Endotoxin-induced intravascular coagulation: prevention with polymyxinB sulfate. J Lab Clin Med 1971; 77: 802-810.

38.

Flynn P.M. , Shenep J.L. , Stokes D.C. , Fairclough D. , Hildner W.K. PolymyxinG moderates acidosis and hypotension in established, experimental gram-negative septicemia. J Infect Dis 1987 ; 156: 706-712.

39.

Hughes B. , Riegle L. PolymyxinB sulfate protects cats against the haemodynamic and metabolic effects of E. coli endotoxin. Br J Pharmacol 1981; 74: 701-707.